Tryton Medical Obtains $5,000,000 New Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b2b85dfd-8055-4cb8-b323-5cee2b3deabd&Preview=1 -
Date
5/3/2011 -
Company Name
Tryton Medical -
Mailing Address
1000 Park Forty Plaza Durham, MA 27713 -
Company Description
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery. -
Website
http://www.trytonmedical.com -
Transaction Type
Debt -
Transaction Amount
$5,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
With the help of this new credit facility, the company is enrolling in a pivotal US clinical trial. -
M&A Terms
-
Venture Investor
Square 1 Bank
